While most prostate cancers initially respond to androgen receptor-blocking therapies, some tumors evolve into a highly aggressive, treatment-resistant form known as neuroendocrine prostate cancer, ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

Obesity has become a global epidemic, and the need for treatment and monitoring for people with obesity is growing.

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by ...

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

In 2015, researchers discovered that some species, like Conus geographus, make venoms that contain con-insulin, a toxin that ...

In a significant contribution to Brain Medicine's Seymour Reichlin Centenary Festschrift, renowned neuroendocrinologist Dr. Philip W. Gold synthesizes decades of research revealing depression's ...

In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including ...

1Department of Neuroscience, UT Southwestern Medical Center, Dallas, Texas. 4Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas. 8Department of Pharmacology, ...